this page only  
Join BIO   |   Member Directory   |    Contact BIO    
Biotechnology Industry Organization

Home
About BIO
Conferences & Events
Past BIO Events
Industry Calendar
State/Int'l Calendar
Members.BIO.org
BIO News Online
BIO Bulletins
Suggestion Box
Membership Directory
BIO Videos
News & Media
BIO Blogs & Podcasts
National Issues
Health
Food & Agriculture
Industrial & Environmental
Bioethics
• Intellectual Property
Regulatory
Tax & Financial
State & Local Issues
State by State Initiatives
Letters, Testimony & Comments
Speeches & Publications
Industry At-a-Glance
Business & Finance
BIO News


Saturday, November 07, 2009

Letter Supporting HR 2215

Click here for a printer-friendly page Printer Friendly PDF

Letter to the Senate strongly supporting the Conference Agreement on the Department of Justice Authorization Act (HR 2215) and urging passage by the U.S. Senate.

October 2, 2002

The Honorable Tom Daschle
United States Senate
509 Hart Senate Office Building
Washington, D.C. 20510

Dear Senator Daschle:

The Biotechnology Industry Organization (BIO) strongly supports the Conference Agreement on the Department of Justice Authorization Act (HR 2215) and urges passage by the U.S. Senate. The House of Representatives passed the measure on September 28, 2002, by a vote of 400 to 4. Enactment of this legislation will strengthen patent protection for biotechnology companies, which rely heavily on intellectual property to obtain capital for life-saving biomedical research and development.

The Conference Agreement includes significant patent law improvements that BIO has advocated for more than two years. The patent provisions included in the Conference Agreement would: 1) provide for reauthorization of essential funding for the Patent and Trademark Office (PTO); 2) clarify prior art standards in the Patent Act; and 3) streamline the patent reexamination process at PTO.

Many of the provisions in the Conference Agreement have been pending before Congress for more than a year. Several of these important patent-related provisions have previously been passed as separate measures by both the House and Senate. Passage of the Department of Justice Authorization Act will ensure predictability in the outcome of patent validity questions and will permit the federal courts to address longstanding legal issues facing the biotechnology industry.

The Biotechnology Industry Organization represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.

We urge the Senate to pass the Conference Agreement on H.R. 2215 without delay. If you have questions, please contact Sharon Cohen, BIO's vice president for government relations, at 202-962-9200.

Sincerely,

 

Carl B. Feldbaum
President

CBF:fc

contact us | terms of use | privacy policy
© 2009 | Biotechnology Industry Organization | 1201 Maryland Ave., SW, Ste. 900 | Washington, D.C. 20024